Exclusive financial advisor to Takeda within the successful sale of its Swiss home delivery business
In late March 2021, the Swiss affiliate of the global pharmaceutical company Takeda successfully divested part of its home delivery business to a Swiss partner who will provide these services on behalf of Takeda in the future. The divestment also included an existing Pharmacy serving part of the German-speaking region of Switzerland.
Through these divestments, Takeda will further focus on the development and marketing of its core products. At the same time, the transaction is intended to continue and further build on the existing standards of patients in Switzerland. In addition, the pharmacy will continue to service the local community.
Support by IFBC
IFBC acted as exclusive M&A advisor to Takeda during the entire transaction process. IFBC supported Takeda in preparing and structuring the transaction, conducted a targeted buyer approach, coordinated the due diligence, and supported the contract negotiations.
You can find out more about our M&A projects and transactions here.
Takeda is a global, R&D-driven biopharmaceutical leader headquartered in Japan. Takeda focuses on four therapeutic areas: oncology, rare genetic and hematology, neuroscience, and gastroenterology. Over 50’000 Takeda employees are committed to improving quality of life for patients and to working with partners in health care in more than 70 countries.
Further information on Takeda can be found here.